Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485628 | 0.90 | MAPT (0.56) | KDM4EMAPTALDH1A1HPGDCYP1A2 | |
| SCHEMBL6481036 | 0.90 | MEN1 (0.52) | KDM4EMAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL6496536 | 0.88 | HIF1A (0.55) | KDM4EMAPTALDH1A1HPGDCYP1A2 | |
| SCHEMBL6498108 | 0.88 | DHFR (0.54) | KDM4EMAPTALDH1A1HPGDCYP1A2 | |
| SCHEMBL6483861 | 0.87 | MAPT (0.56) | KDM4EMAPTALDH1A1HPGDCYP1A2 | |
| SCHEMBL6494176 | 0.87 | HIF1A (0.49) | KDM4EMAPTALDH1A1HPGDCYP1A2 | |
| SCHEMBL6483874 | 0.83 | HPGD (0.63) | KDM4EMAPTALDH1A1HPGDCYP1A2 | |
| SCHEMBL6484790 | 0.83 | MAPT (0.57) | KDM4EMAPTALDH1A1HPGDNPSR1 | |
| SCHEMBL6481670 | 0.82 | MAOB (0.46) | KDM4EMAPTALDH1A1HPGDMEN1 | |
| SCHEMBL6482218 | 0.80 | MAPT (0.48) | KDM4EMAPTALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | claimed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | claimed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | claimed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | claimed |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | disclosed |
| JP-2005023463-A | SHEATH/CORE CONJUGATE-TYPE ELECTRICALLY CONDUCTIVE FIBER | KANEBO LTD | 2005-01-27 | — | — | JP | disclosed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | disclosed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | HDAC8, ZC3HAV1, ZCCHC8 | KDM4E 1279/4885MAPT 2337/4885ALDH1A1 4486/4885 |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | HDAC8, CDK8, ZC3HAV1 | KDM4E 1476/4885MAPT 3500/4885ALDH1A1 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.